Literature DB >> 12509442

Double-stranded RNA signaling by Toll-like receptor 3 requires specific tyrosine residues in its cytoplasmic domain.

Saumendra N Sarkar1, Heather L Smith, Theresa M Rowe, Ganes C Sen.   

Abstract

Double-stranded (ds) RNA, a common product of viral infection, can induce transcription of many cellular genes, including the 561 gene that encodes P56, a regulator of protein synthesis. Here, we report that induction of the 561 mRNA by exogenous dsRNA is mediated by Toll-like receptor 3 (TLR3), and it requires no new protein synthesis. Because gene induction by dsRNA is blocked by inhibitors of tyrosine kinases, we investigated the potential roles of the five tyrosine residues present in the cytoplasmic domain of TLR3 by their individual and combinatorial mutations. Transfection assays, using a reporter gene driven by the 561 promoter, identified specific tyrosine residues to be essential for TLR3 signaling. This conclusion was further validated in permanent cell lines expressing tyrosine-mutant TLR3 proteins; in some of these cell lines dsRNA failed to induce the 561 mRNA. Our results provide the first demonstration of the importance of TLR3 cytoplasmic tyrosine residues in dsRNA signaling.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12509442     DOI: 10.1074/jbc.C200655200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Molecular characterization of coding sequences and analysis of Toll-like receptor 3 mRNA expression in water buffalo (Bubalus bubalis) and nilgai (Boselaphus tragocamelus).

Authors:  Animesh Dhara; Mohini Saini; Dhanjit K Das; Devendra Swarup; Bhaskar Sharma; Satish Kumar; Praveen K Gupta
Journal:  Immunogenetics       Date:  2006-11-21       Impact factor: 2.846

Review 2.  New players in TLR-mediated innate immunity: PI3K and small Rho GTPases.

Authors:  Monica Ruse; Ulla G Knaus
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 3.  Toll-like receptors and leishmaniasis.

Authors:  Felipe F Tuon; Valdir S Amato; Hélio A Bacha; Tariq Almusawi; Maria I Duarte; Vicente Amato Neto
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

4.  Toll-like receptor 3 regulates Mx expression in rare minnow Gobiocypris rarus after viral infection.

Authors:  Jianguo Su; Zuoyan Zhu; Yaping Wang; Jun Zou; Wei Hu
Journal:  Immunogenetics       Date:  2008-03-28       Impact factor: 2.846

5.  Myeloid differentiation factor-2 interacts with Lyn kinase and is tyrosine phosphorylated following lipopolysaccharide-induced activation of the TLR4 signaling pathway.

Authors:  Pearl Gray; Jargalsaikhan Dagvadorj; Kathrin S Michelsen; Constantinos Brikos; Altan Rentsendorj; Terrence Town; Timothy R Crother; Moshe Arditi
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

Review 6.  Activation of GPR15 and its involvement in the biological effects of smoking.

Authors:  Sulev Kõks; Gea Kõks
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-19

Review 7.  Traditional biochemical assays for studying toll-like receptor 9.

Authors:  Cynthia A Leifer; William A Rose; Fernando Botelho
Journal:  J Immunoassay Immunochem       Date:  2013

8.  The inducible nitric-oxide synthase (iNOS)/Src axis mediates Toll-like receptor 3 tyrosine 759 phosphorylation and enhances its signal transduction, leading to interferon-β synthesis in macrophages.

Authors:  Ming-Yu Hsieh; Miao Ying Chang; Yen-Jen Chen; Yung Kuo Li; Tsung-Hsien Chuang; Guann-Yi Yu; Chun Hei Antonio Cheung; Hui-Chen Chen; Ming-Chei Maa; Tzeng-Horng Leu
Journal:  J Biol Chem       Date:  2014-02-13       Impact factor: 5.157

Review 9.  Sensing of viral infection and activation of innate immunity by toll-like receptor 3.

Authors:  Elisabeth Vercammen; Jens Staal; Rudi Beyaert
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

10.  Myd88 is required for an antibody response to retroviral infection.

Authors:  Edward P Browne; Dan R Littman
Journal:  PLoS Pathog       Date:  2009-02-13       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.